TY - JOUR
T1 - Suppression of NK cell activity and of resistance to metastasis by stress
T2 - A role for adrenal catecholamines and β-adrenoceptors
AU - Ben-Eliyahu, Shamgar
AU - Shakhar, Guy
AU - Page, Gayle G.
AU - Stefanski, Volker
AU - Shakhar, Keren
PY - 2000
Y1 - 2000
N2 - Although acute stress has been reported to suppress natural killer cell activity (NKA) and host resistance to metastasis, it is unclear whether the sympathetic nervous system (SNS) has a role in these effects. The current study in Fischer 344 rats assessed the involvement of adrenal catecholamines and β1- and β2-adrenoceptors in mediating these deleterious effects of swim stress. In addition to assessing the number and activity of NK cells following swim stress, we used a tumor model based on the MADB106 mammary adenocarcinoma line: this syngeneic tumor metastasizes only to the lungs, and its lung tumor retention (LTR) and metastatic colonization are highly sensitive to NKA. The findings indicate that stress increased both LTR, assessed 24 h after inoculation, and the number of lung metastases, counted 3 weeks later. These effects were attenuated or completely abolished by the ganglionic blocker chlorisondamine (3 mg/kg i.p.), by adrenal demedullation, by a selective β-adrenergic antagonist (nadolol, 0.4 mg/kg), and additively by a selective β1- (atenolol, 1-6 mg/kg) and a selective β2-antagonist (either butoxamine 4-32 mg/kg or ICI-118,551 0.3-8 mg/kg). Stress also suppressed NKA, and adrenal demedullation prevented this suppression. Administration of adrenaline (0.1-1 mg/kg) or of a β-adrenergic agonist (metaproterenol, 0.8 mg/kg), in physiologically relevant doses, suppressed NKA in a dose-dependent manner, and increased LTR to levels characteristic of swim stress. Taken together, these findings suggest that acute stress, by releasing catecholamines from the adrenal glands and activating β1- and β2-adrenoceptors, suppresses NKA and consequently compromises resistance to NK-sensitive metastasis.
AB - Although acute stress has been reported to suppress natural killer cell activity (NKA) and host resistance to metastasis, it is unclear whether the sympathetic nervous system (SNS) has a role in these effects. The current study in Fischer 344 rats assessed the involvement of adrenal catecholamines and β1- and β2-adrenoceptors in mediating these deleterious effects of swim stress. In addition to assessing the number and activity of NK cells following swim stress, we used a tumor model based on the MADB106 mammary adenocarcinoma line: this syngeneic tumor metastasizes only to the lungs, and its lung tumor retention (LTR) and metastatic colonization are highly sensitive to NKA. The findings indicate that stress increased both LTR, assessed 24 h after inoculation, and the number of lung metastases, counted 3 weeks later. These effects were attenuated or completely abolished by the ganglionic blocker chlorisondamine (3 mg/kg i.p.), by adrenal demedullation, by a selective β-adrenergic antagonist (nadolol, 0.4 mg/kg), and additively by a selective β1- (atenolol, 1-6 mg/kg) and a selective β2-antagonist (either butoxamine 4-32 mg/kg or ICI-118,551 0.3-8 mg/kg). Stress also suppressed NKA, and adrenal demedullation prevented this suppression. Administration of adrenaline (0.1-1 mg/kg) or of a β-adrenergic agonist (metaproterenol, 0.8 mg/kg), in physiologically relevant doses, suppressed NKA in a dose-dependent manner, and increased LTR to levels characteristic of swim stress. Taken together, these findings suggest that acute stress, by releasing catecholamines from the adrenal glands and activating β1- and β2-adrenoceptors, suppresses NKA and consequently compromises resistance to NK-sensitive metastasis.
KW - Immunomodulators
KW - In vivo animal models
KW - NK cells
KW - Neuroimmunology
KW - Rodent
UR - http://www.scopus.com/inward/record.url?scp=0034532188&partnerID=8YFLogxK
U2 - 10.1159/000054276
DO - 10.1159/000054276
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 11124582
AN - SCOPUS:0034532188
SN - 1021-7401
VL - 8
SP - 154
EP - 164
JO - NeuroImmunoModulation
JF - NeuroImmunoModulation
IS - 3
ER -